BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 33220463)

  • 1. Enhancing anti-melanoma outcomes in mice using novel chitooligosaccharide nanoparticles loaded with therapeutic survivin-targeted siRNA.
    Liu X; Chen L; Zhang Y; Xin X; Qi L; Jin M; Guan Y; Gao Z; Huang W
    Eur J Pharm Sci; 2021 Mar; 158():105641. PubMed ID: 33220463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a carrier system containing hyaluronic acid and protamine for siRNA delivery in the treatment of melanoma.
    Yang J; Zhao R; Feng Q; Zhuo X; Wang R
    Invest New Drugs; 2021 Feb; 39(1):66-76. PubMed ID: 32794135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chitosan-based nanoparticles for survivin targeted siRNA delivery in breast tumor therapy and preventing its metastasis.
    Sun P; Huang W; Jin M; Wang Q; Fan B; Kang L; Gao Z
    Int J Nanomedicine; 2016; 11():4931-4945. PubMed ID: 27729789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-tumor effects in mice induced by survivin-targeted siRNA delivered through polysaccharide nanoparticles.
    Yang F; Huang W; Li Y; Liu S; Jin M; Wang Y; Jia L; Gao Z
    Biomaterials; 2013 Jul; 34(22):5689-99. PubMed ID: 23632321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Silencing of survivin and cyclin B1 through siRNA-loaded arginine modified calcium phosphate nanoparticles for non-small-cell lung cancer therapy.
    Kara G; Parlar A; Cakmak MC; Cokol M; Denkbas EB; Bakan F
    Colloids Surf B Biointerfaces; 2020 Dec; 196():111340. PubMed ID: 32956996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular uptake mechanism and knockdown activity of siRNA-loaded biodegradable DEAPA-PVA-g-PLGA nanoparticles.
    Benfer M; Kissel T
    Eur J Pharm Biopharm; 2012 Feb; 80(2):247-56. PubMed ID: 22085653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene-silencing effects of anti-survivin siRNA delivered by RGDV-functionalized nanodiamond carrier in the breast carcinoma cell line MCF-7.
    Bi Y; Zhang Y; Cui C; Ren L; Jiang X
    Int J Nanomedicine; 2016; 11():5771-5787. PubMed ID: 27853365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcutaneous iontophoretic delivery of STAT3 siRNA using layer-by-layer chitosan coated gold nanoparticles to treat melanoma.
    Labala S; Jose A; Venuganti VV
    Colloids Surf B Biointerfaces; 2016 Oct; 146():188-97. PubMed ID: 27318964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination Therapy of Breast Cancer by Codelivery of Doxorubicin and Survivin siRNA Using Polyethylenimine Modified Silk Fibroin Nanoparticles.
    Norouzi P; Motasadizadeh H; Atyabi F; Dinarvand R; Gholami M; Farokhi M; Shokrgozar MA; Mottaghitalab F
    ACS Biomater Sci Eng; 2021 Mar; 7(3):1074-1087. PubMed ID: 33539074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Silencing of the metastasis-linked gene, AEG-1, using siRNA-loaded cholamine surface-modified gelatin nanoparticles in the breast carcinoma cell line MCF-7.
    Abozeid SM; Hathout RM; Abou-Aisha K
    Colloids Surf B Biointerfaces; 2016 Sep; 145():607-616. PubMed ID: 27285732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioreducible Cross-Linked Hyaluronic Acid/Calcium Phosphate Hybrid Nanoparticles for Specific Delivery of siRNA in Melanoma Tumor Therapy.
    Zhou Z; Li H; Wang K; Guo Q; Li C; Jiang H; Hu Y; Oupicky D; Sun M
    ACS Appl Mater Interfaces; 2017 May; 9(17):14576-14589. PubMed ID: 28393529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic siRNA Delivery with a Dual pH-Responsive and Tumor-targeted Nanovector for Inhibiting Tumor Growth and Spontaneous Metastasis in Orthotopic Murine Model of Breast Carcinoma.
    Fan B; Kang L; Chen L; Sun P; Jin M; Wang Q; Bae YH; Huang W; Gao Z
    Theranostics; 2017; 7(2):357-376. PubMed ID: 28042340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Layer-by-layer nanoparticles as an efficient siRNA delivery vehicle for SPARC silencing.
    Tan YF; Mundargi RC; Chen MH; Lessig J; Neu B; Venkatraman SS; Wong TT
    Small; 2014 May; 10(9):1790-8. PubMed ID: 24510544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy.
    Chen Y; Zhu X; Zhang X; Liu B; Huang L
    Mol Ther; 2010 Sep; 18(9):1650-6. PubMed ID: 20606648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Core-shell type lipid/rPAA-Chol polymer hybrid nanoparticles for in vivo siRNA delivery.
    Gao LY; Liu XY; Chen CJ; Wang JC; Feng Q; Yu MZ; Ma XF; Pei XW; Niu YJ; Qiu C; Pang WH; Zhang Q
    Biomaterials; 2014 Feb; 35(6):2066-78. PubMed ID: 24315577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sialic Acid-Targeted Nanovectors with Phenylboronic Acid-Grafted Polyethylenimine Robustly Enhance siRNA-Based Cancer Therapy.
    Ji M; Li P; Sheng N; Liu L; Pan H; Wang C; Cai L; Ma Y
    ACS Appl Mater Interfaces; 2016 Apr; 8(15):9565-76. PubMed ID: 27007621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and anti-tumor activity of self-loaded nanocarriers of siRNA.
    Han W; Yuan Y; Li H; Fu Z; Wang M; Guan S; Wang L
    Colloids Surf B Biointerfaces; 2019 Nov; 183():110385. PubMed ID: 31408781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced Cellular Uptake and Gene Silencing Activity of Survivin-siRNA via Ultrasound-Mediated Nanobubbles in Lung Cancer Cells.
    Akbaba H; Erel-Akbaba G; Kotmakçı M; Başpınar Y
    Pharm Res; 2020 Aug; 37(8):165. PubMed ID: 32761250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted nanoparticles deliver siRNA to melanoma.
    Chen Y; Bathula SR; Yang Q; Huang L
    J Invest Dermatol; 2010 Dec; 130(12):2790-8. PubMed ID: 20686495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biocompatible gelatin nanoparticles for tumor-targeted delivery of polymerized siRNA in tumor-bearing mice.
    Lee SJ; Yhee JY; Kim SH; Kwon IC; Kim K
    J Control Release; 2013 Nov; 172(1):358-366. PubMed ID: 24036198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.